The Real Risks of Wegovy — and How to Think About Them

The side effects most people actually encounter

The practical question most people bring to this topic is not whether Wegovy has risks (it does) but which ones are likely, which are rare, and which are serious enough to change the decision entirely.

Nausea is the most reported side effect, and it is worth understanding why: semaglutide slows the rate at which your stomach empties, which is central to how the medicine works but also the reason food can feel unwelcome, especially first thing in the morning. Vomiting, diarrhoea, constipation, reflux and burping sit in the same family. The NHS semaglutide guidance describes these as common effects that are usually transient, settling as your body adjusts. They tend to peak after the first injection or after each dose step upward, not as a steady feature of treatment.

Fatigue, headache and dizziness are also recorded, though less frequently. Injection-site reactions (mild redness or discomfort where you inject) are generally minor and short-lived. If you want a fuller picture of what the ongoing experience looks like, our page on Wegovy side effects after six months covers how the profile tends to shift once your body has settled into treatment. Common Wegovy side effects covers the early phase in more detail.

Taken together, for most people the GI effects are manageable rather than limiting. That said, they are real, and anyone who has had severe nausea before will rightly want to factor that in.

The serious risks that require a clinical conversation

Beyond the common GI effects, a smaller group of risks warrants a different level of attention, not because they are likely, but because they can be serious.

Acute pancreatitis is the most significant one to know about. On 29 January 2026, the MHRA published a Drug Safety Update confirming it as a known, infrequent but potentially serious risk associated with GLP-1 medicines including semaglutide. The signal to act on is severe stomach pain that is persistent and may radiate toward the back, with or without vomiting. That is not ordinary nausea: it needs same-day medical assessment, not a wait-and-see approach.

Gallbladder problems (including gallstones and inflammation) have been reported more often in people on semaglutide than in those on placebo in clinical trials. The mechanism is thought to be related to reduced gallbladder movement as food intake changes. People with a history of gallstones should raise this at consultation.

There is also a theoretical concern about thyroid C-cell tumours, based on findings in rodent studies; no causal link has been established in humans, but Wegovy is not recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. A prescriber will ask about this. You can read more about this specific question on our page covering Wegovy and cancer risk, which covers what the evidence actually shows.

Dehydration is worth flagging too: severe vomiting or diarrhoea, if prolonged, can strain the kidneys. Staying hydrated and knowing when to seek help matters.

When to get medical help, and what counts as urgent

This distinction is the practical heart of any safety discussion about Wegovy. Most side effects are self-limiting and do not need urgent care. A handful do.

Seek same-day medical attention (call 111 or go to A&E if your GP is unavailable) if you experience: severe stomach pain that persists or spreads to your back (possible pancreatitis, as flagged in the January 2026 MHRA update); signs of a serious allergic reaction such as swelling of the face, lips or throat, or difficulty breathing; symptoms of severe dehydration after prolonged vomiting or diarrhoea; or any signs of gallbladder problems such as sudden severe pain in the upper right abdomen.

Contact your prescriber or a pharmacist if you notice persistent nausea that is stopping you from eating adequately, worsening mental health or low mood, or any change that concerns you but does not feel like an emergency.

Suspected side effects can be reported to the MHRA directly at yellowcard.mhra.gov.uk, patients can submit reports themselves, and doing so helps build the UK safety picture for newer medicines. If you are a nume patient, our prescribers are on hand seven days a week: contact the team any time aftercare is needed.

How these risks are weighed against the benefits (and the role of clinical oversight

Understanding Wegovy risk means holding two things at once: these side effects are real, and the conditions that Wegovy is licensed to treat) obesity and the cardiovascular and metabolic conditions it drives, carry serious health consequences of their own. The STEP 1 trial, published in the New England Journal of Medicine, found an average 15% reduction in body weight over 68 weeks at the 2.4mg maintenance dose in people without diabetes. NICE assessed this evidence before recommending semaglutide, concluding the benefit-risk profile was favourable for the right population.

That caveat matters. The "right population" is defined by clinical assessment, not self-selection. A prescriber looks at your weight, existing health conditions, current medications, and relevant history before deciding whether Wegovy is appropriate and at what starting point. For a broader overview of how the risks stack up overall, our guide to Wegovy risks and the page on whether Wegovy is worth the risk go deeper on this weighing process.

At nume, the consultation is reviewed the same day by a named GPhC-registered Independent Prescriber, a real clinician reading your answers, not automated decision software. Your pen, if approved, arrives via DPD the next working day in plain, unbranded packaging; the tracking notification comes to your phone. Discreet, but more importantly, supervised. See our Wegovy overview for how the full process works, or learn about individual risk factors that a prescriber will consider. Our clinical team can discuss suitability and walk through any concerns as part of a free consultation.